Marker Therapeutics, Inc. MRKR 深 滬
等待開盤 10-13 09:30:00 美东时间
1.01
-0.040
-3.81%
華盛通- 最 高1.094
- 今 開1.06
- 成交量 25.78万股
- 最 低 0.991
- 昨 收 1.05
- 總市值 1306.83万
- 52周最高 5.95
- 市盈率 靜 --
- 換手率 1.99%
- 52周最低 0.8099
- 委 比 92.80%
- 總股本 1293.89万
- 歷史最高 99.00
- 量 比 0.51
- 振 幅 9.81%
- 歷史最低 0.8099
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Marker Therapeutics Announces First Patient Treated In OTS Program, With Encouraging Preliminary Safety Data
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatmentOTS product was well tolerated - safety data
10-06 19:33
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated its Off-the-Shelf (OTS) program for multi-antigen recognizing (MAR) T cells, with the first patient treated in the Phase 1 RAPID study. The OTS product targeting four tumor antigens demonstrated encouraging safety data with no treatment-related adverse events. The study focuses on patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with potential expansion to other indications. The company ...
10-06 11:30
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Phase 1 APOLLO study of MT-601 shows 66% objective response rate in NHL patients, with 50% achieving complete response. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or ICANS. The study will expand to investigate MT-601 at the maximum dose in DLBCL patients who relapsed after or are ineligible for CAR-T therapy. A live webcast discussing the results will be held today.
08-26 11:00
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics' CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The session will focus on the Company's MAR T cell platform and clinical developments. Investors can access the webcast via Marker's Investor Relations website.
07-30 12:00
Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor
06-17 20:08
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics collaborates with Cellipont Bioservices to manufacture MT-601, a Multi-Antigen Recognizing T cell therapy for lymphoma patients. MT-601 has shown promising results in the Phase 1 APOLLO study, with 78% of participants experiencing objective responses. The partnership aims to accelerate clinical supply and prepare for potential pivotal trials. Both companies emphasize their commitment to advancing innovative immunotherapies to ...
06-17 12:00
Marker Therapeutics Concludes Annual Stockholders Meeting
Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 6, 2025, Marke...
06-10 04:28
Marker Therapeutics To Highlight Multi-Antigen Recognizing-T Cells In High-Profile Panel On CAR-T Cell Therapies
MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid
05-19 20:10
美股大行评级 | 潜在涨幅4159%！HC Wainwright & Co.上调BiomX目标价至21美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114111385008877568.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BiomX(PHGE)"买入"评级，目标价从2美元升至21美元</p> <p>• HC Wainwright & Co.：维持Unicycive Therapeu
04-02 09:42
美股机会日报丨美股期指大跌！华尔街模型预测衰退概率最高达50%
美股指数盘前重挫！标普500指数期货跌1.25%，英伟达跌超3%；华尔街模型预测衰退概率最高达50%；京东盘前涨超6%，拟回购最多50亿美元股票>>
03-06 21:11
